Table 2 Diagnostic test performance of furosemide stress test for AKI progression, renal replacement therapy, and mortality
Study | Sensitivity | Specificity | Sample size | Event (AKI progression) | TP | FP | FN | TN | Follow-up period |
Chawla, 2013 [8] | 87.1 | 84.1 | 77 | 25 | 22 | 8 | 3 | 44 | 14 days |
Elsaegh, 2018 [14] | 89.3 | 93.4 | 60 | 28 | 25 | 2 | 3 | 30 | NA |
Martínez, 2016 [16] | 66.7 | 100 | 20 | 6 | 4 | 0 | 2 | 14 | 30 days |
Matsuura, 2018 [17] | 76.5 | 94.1 | 51 | 17 | 13 | 2 | 4 | 32 | 7 days |
Pérez-Cruz, 2017 [18] | 57.1 | 95.2 | 35 | 14 | 8 | 1 | 6 | 20 | NA |
Saber, 2018 [20] | 86.7 | 68 | 40 | 15 | 13 | 8 | 2 | 17 | NA |
Rewa, 2019 [19] | 73.9 | 90 | 92 | 23 | 17 | 7 | 6 | 62 | 30 days |
Vairakkani, 2019 [22] | 82 | 80.8 | 80 | 28 | 23 | 10 | 5 | 42 | 14 days |
Venugopal, 2019 [24] | 85.7 | 87.5 | 62 | 14 | 12 | 6 | 2 | 42 | NA |
Study | Sensitivity | Specificity | Sample size | Event (RRT) | TP | FP | FN | TN | Follow-up period |
Lumlertgul, 2018 [15] | 94.4 | 70.4 | 162 | 108 | 102 | 16 | 6 | 38 | 28 days |
Martínez, 2016 [16] | 75 | 93.7 | 20 | 4 | 3 | 1 | 1 | 15 | 30 days |
Matsuura, 2018 [17] | 75 | 79 | 51 | 8 | 6 | 9 | 2 | 34 | 7 days |
Pérez-Cruz, 2017 [18] | 62.5 | 85.2 | 35 | 8 | 5 | 4 | 3 | 23 | NA |
Sakhuja, 2019 [21] | 80.9 | 50.5 | 687 | 162 | 131 | 260 | 31 | 265 | 1 day |
Venugopal, 2019 [23] | 83.3 | 84 | 62 | 12 | 10 | 8 | 2 | 42 | NA |
Study | Sensitivity | Specificity | Sample size | Event (mortality) | TP | FP | FN | TN | Follow-up period |
Martínez, 2016 [16] | 20 | 80 | 20 | 5 | 1 | 3 | 4 | 12 | 30 days |
Venugopal, 2019 [23] | 66.7 | 77.3 | 62 | 9 | 6 | 12 | 3 | 41 | NA |